Clinical trial shows finerenone reduces kidney failure risk by 24% in CKD patients — Evidence Review
Published in The Lancet, The New England Journal of Medicine, JAMA, by researchers from The George Institute for Global Health, UNSW Sydney
Researched by
— the AI search engine for science
Table of Contents
Large-scale international research indicates that finerenone, a kidney disease medication, significantly reduces the risk of kidney failure, cardiovascular complications, and death in a broader chronic kidney disease (CKD) population—not just those with diabetes. Most related studies support these findings, showing finerenone’s benefits for kidney and cardiovascular outcomes in diabetic CKD and suggesting emerging support for its use in non-diabetic CKD as well, as highlighted by The George Institute for Global Health.
- Previous large randomized trials have consistently demonstrated that finerenone reduces kidney disease progression and major cardiovascular events in patients with type 2 diabetes and CKD, aligning with the new study’s findings of benefit in broader CKD populations 1 2 3.
- Recent meta-analyses rank finerenone and other mineralocorticoid receptor antagonists (MRAs) just behind SGLT-2 inhibitors for kidney and cardiovascular risk reduction in type 2 diabetes with CKD, reinforcing the new results and supporting their expansion beyond diabetic populations 13.
- Prior research has shown MRAs carry a risk of hyperkalemia, and the new study confirms that while finerenone increases this risk, treatment discontinuation due to hyperkalemia remains relatively uncommon 1 13.
Study Overview and Key Findings
Chronic kidney disease is a global health concern affecting approximately 850 million people and is projected to become a leading cause of premature death by 2040. While diabetes is a major cause, most CKD patients are non-diabetic and have limited effective treatment options. This study is notable for its breadth, investigating finerenone’s effects not only in diabetic CKD—where its benefits are well documented—but also in non-diabetic CKD and glomerular diseases, populations for which evidence has been sparse. The study’s simultaneous publication in three major medical journals underscores its importance.
| Property | Value |
|---|---|
| Organization | The George Institute for Global Health, UNSW Sydney |
| Journal Name | The Lancet, The New England Journal of Medicine, JAMA |
| Authors | Professor Hiddo Heerspink, Professor Vlado Perkovic, Associate Professor Brendon Neuen |
| Population | Patients with chronic kidney disease (CKD) |
| Sample Size | 1,584 participants |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Kidney function decline, cardiovascular complications, survival |
| Results | Finerenone reduced kidney failure risk by 24% and death risk by 12%. |
Literature Review: Related Studies
To place these new findings in context, we searched the Consensus paper database, which contains over 200 million research papers. The following queries were used to identify recent and relevant studies:
- finerenone kidney failure risk
- finerenone death risk reduction
- kidney drugs patient outcomes comparison
Literature Summary Table
| Topic | Key Findings |
|---|---|
| What are the kidney and cardiovascular benefits of finerenone in CKD and diabetes? | - Finerenone reduces kidney disease progression and cardiovascular events in patients with CKD and type 2 diabetes 1 2 3. - It also reduces new-onset heart failure and improves overall cardiovascular outcomes, regardless of heart failure history 4. |
| How does finerenone compare to other established CKD treatments (e.g., ACE inhibitors, ARBs, SGLT-2 inhibitors)? | - ACE inhibitors and ARBs remain first-line agents for CKD, but finerenone provides additional benefit, particularly for reducing albuminuria and slowing progression when used with standard therapy 9 10 11 13. - SGLT-2 inhibitors are currently considered optimal for reducing composite kidney and cardiovascular events, with MRAs like finerenone offering additive benefits but higher hyperkalemia risk 13. |
| What is the safety profile of finerenone, particularly risk of hyperkalemia? | - Finerenone increases the risk of hyperkalemia compared to placebo, but rates of serious adverse events and treatment discontinuation remain low 1 2 3 13. - The risk profile is similar to, or potentially lower than, older steroidal MRAs, supporting its use in carefully monitored patients 1 13. |
| Can finerenone benefit non-diabetic CKD or glomerular disease populations? | - Preliminary evidence, including the new study, suggests finerenone benefits extend to non-diabetic CKD and glomerular diseases, but more dedicated trials are needed [current study]. - Prior research has focused predominantly on diabetic CKD, leaving a gap that the current study begins to address 1 2 3 4. |
What are the kidney and cardiovascular benefits of finerenone in CKD and diabetes?
A substantial body of research supports finerenone’s efficacy in reducing kidney disease progression and cardiovascular complications in patients with CKD and type 2 diabetes. The new study confirms these benefits and extends them to non-diabetic CKD populations, marking an important advance in CKD therapy.
- Large RCTs (FIDELIO-DKD, FIGARO-DKD) consistently show finerenone lowers the risk of kidney failure and cardiovascular events in diabetic CKD 1 2.
- Meta-analyses demonstrate a robust reduction in major adverse kidney and cardiovascular outcomes with finerenone versus placebo 3 8.
- The new study’s findings of benefit in non-diabetic CKD mirror those previously seen in diabetes, suggesting a potentially broader role for the drug [current study].
- Cardiovascular benefits include reduced rates of heart failure hospitalization and cardiovascular death 2 3 4 8.
How does finerenone compare to other established CKD treatments (e.g., ACE inhibitors, ARBs, SGLT-2 inhibitors)?
Finerenone offers additive benefits to standard-of-care agents such as ACE inhibitors or ARBs, especially in patients with albuminuria. However, SGLT-2 inhibitors currently have the most robust evidence for reducing both kidney and cardiovascular events in diabetic CKD, with MRAs like finerenone providing further risk reduction when used in combination.
- ACE inhibitors and ARBs are highly effective in lowering the risk of kidney failure and cardiovascular events and remain first-line therapy in CKD 9 10 11.
- Network meta-analyses suggest MRAs, including finerenone, provide additional benefit on top of ACE inhibitors/ARBs, particularly for reducing proteinuria and progression 13.
- SGLT-2 inhibitors are associated with the greatest reductions in composite kidney events and are recommended as foundational therapy; adding finerenone may further reduce risk, but increases hyperkalemia 13.
- The current study’s results support the adjunctive use of finerenone, especially in patients unable to tolerate SGLT-2 inhibitors or with persistent albuminuria [current study, 13].
What is the safety profile of finerenone, particularly risk of hyperkalemia?
Safety concerns with MRAs focus on hyperkalemia, a potentially serious electrolyte imbalance. Finerenone, a non-steroidal MRA, has a more favorable safety profile compared to older agents, but still increases hyperkalemia risk.
- Both FIDELIO-DKD and FIGARO-DKD trials reported higher rates of hyperkalemia with finerenone compared to placebo, but treatment discontinuation due to hyperkalemia was uncommon 1 2.
- Meta-analyses confirm a higher risk of hyperkalemia with MRAs versus other agents, but most events are mild and manageable with monitoring 13.
- The new study found similar results: while hyperkalemia was more frequent, serious complications were rare and did not often require stopping treatment [current study, 1].
- Comparisons to steroidal MRAs suggest finerenone may have a lower risk of other adverse events, such as gynecomastia, supporting its role in CKD management 1 13.
Can finerenone benefit non-diabetic CKD or glomerular disease populations?
Historically, research and clinical trials of finerenone have focused on diabetic CKD. The new study is among the first large trials to provide evidence of benefit in non-diabetic CKD and glomerular diseases, addressing a significant unmet need.
- The current study demonstrates significant kidney and cardiovascular benefits in non-diabetic CKD and glomerular disease subgroups [current study].
- Previous research in these populations is limited, with most MRAs studied in diabetes or mixed cohorts 1 2 3 4.
- These findings suggest a potentially broader role for finerenone, but additional dedicated trials are needed to confirm efficacy and safety in non-diabetic populations [current study].
- Ongoing studies may further clarify which non-diabetic CKD subgroups benefit most from finerenone therapy [current study].
Future Research Questions
Despite encouraging findings, further research is needed to clarify finerenone’s role in diverse CKD populations, optimize combination therapy strategies, and ensure long-term safety. The following questions highlight areas for future investigation:
| Research Question | Relevance |
|---|---|
| What is the long-term safety and efficacy of finerenone in non-diabetic CKD populations? | Large-scale data in non-diabetic CKD are limited; the new study provides initial evidence, but longer follow-up and larger cohorts are needed to confirm sustained benefit and monitor for adverse events [current study]. |
| How does finerenone compare to SGLT-2 inhibitors for kidney and cardiovascular outcomes in CKD? | SGLT-2 inhibitors have robust evidence for both kidney and cardiovascular protection; understanding the relative and additive benefits of finerenone versus SGLT-2 inhibitors will inform optimal treatment strategies 13. |
| What are the risks and management strategies for hyperkalemia with finerenone in real-world practice? | Controlled trials show manageable hyperkalemia risk, but real-world data are needed to identify patient subgroups at greatest risk and optimize monitoring and mitigation strategies 1 2 13. |
| Does combining finerenone with SGLT-2 inhibitors provide additive benefit in CKD patients? | Combination therapy may maximize risk reduction but could increase adverse events; randomized trials are needed to determine efficacy, safety, and optimal patient selection for combined use 13. |
| Which CKD subgroups derive the greatest benefit from finerenone treatment? | The new study suggests benefits across diverse CKD etiologies, but more granular analyses are needed to tailor therapy to specific populations, including those with glomerular disease, varying degrees of proteinuria, or different comorbidities. |
In summary, new evidence supports expanding finerenone use to a broader CKD population, with benefits for kidney and cardiovascular outcomes. Related studies largely corroborate these findings in diabetic CKD and suggest potential for additive benefit—though future research should address long-term safety, optimal combinations with other therapies, and efficacy in non-diabetic CKD subgroups.